{"id":12053,"date":"2025-03-13T23:41:21","date_gmt":"2025-03-13T22:41:21","guid":{"rendered":"https:\/\/valintermed.com\/?p=12053"},"modified":"2025-03-13T23:41:21","modified_gmt":"2025-03-13T22:41:21","slug":"miasteniya-gravis","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/myasthenia-gravis\/","title":{"rendered":"Myasthenia Gravis"},"content":{"rendered":"
<\/div>\n

Myasthenia gravis is an autoimmune disease characterized by muscle weakness caused by impaired transmission of nerve impulses to the muscles. The main pathogenetic mechanism of the disease is the development of antibodies to nicotinic acetylcholine receptors in the synapses of muscle fibers, which leads to a decrease in the number of these receptors on the postsynaptic membrane and, accordingly, to a decrease in the ability to activate the muscle cell. Clinically, myasthenia gravis manifests itself in episodes of muscle weakness and fatigue, which can vary depending on the load and can increase during the day. This disease can affect any muscle group, but the most common symptoms are those related to the muscles of the eyes, face, throat and extremities.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n